Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Nanomedicine. 2016 Aug 20;13(2):659–665. doi: 10.1016/j.nano.2016.08.004

Figure 1.

Figure 1

GLP-1 nanomedicine attenuates DSS induced colitis in mice. Change in body weight (A), preservation of stool consistency (B) during DSS treatment. Colitis was induced by 3% (wt/vol) DSS supplemented in drinking water for 7 days to DSS and DSS + GLP1-SSM groups. 15 nmol of GLP1-SSM or SSM was administered by i.p injection everyday to mice in respective groups during the 7 days of DSS treatment. Data were expressed as the mean ± SEM, ****P < 0.0001. n = 10 mice per group.